Aperio Group’s PRA Health Sciences, Inc. PRAH Stock Holding History

Aperio Group’s Portfolio PRAH Stock Details PRAH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$5.67M	Buy	45,182 +22,747	+101%	+$2.54M	0.02%	771
2020 Q3	$2.28M	Buy	22,435 +3,264	+17%	+$333K	0.01%	1059
2020 Q2	$1.86M	Buy	19,171 +1,624	+9%	+$151K	0.01%	1143
2020 Q1	$1.46M	Buy	17,547 +2,531	+17%	+$247K	0.01%	1155
2019 Q4	$1.67M	Buy	15,016 +121	+0.8%	+$12.4K	0.01%	1176
2019 Q3	$1.48M	Buy	14,895 +2,487	+20%	+$247K	0.01%	1195
2019 Q2	$1.23M	Sell	12,408 -1,721	-12%	-$164K	0.01%	1301
2019 Q1	$1.56M	Buy	14,129 +894	+7%	+$93.4K	0.01%	1149
2018 Q4	$1.22M	Buy	13,235 +2,517	+23%	+$255K	0.01%	1204
2018 Q3	$1.18M	Buy	10,718 +3,143	+41%	+$327K	0.01%	1314
2018 Q2	$707K	Buy	7,575 +1,393	+23%	+$120K	﹤0.01%	1572
2018 Q1	$513K	Buy	6,182 +2,134	+53%	+$190K	﹤0.01%	1680
2017 Q4	$369K	Buy	4,048 +62	+2%	+$5.16K	﹤0.01%	1845
2017 Q3	$304K	Buy	3,986 +886	+29%	+$67K	﹤0.01%	1914
2017 Q2	$233K	Buy	+3,100	New	+$215K	﹤0.01%	2031

Other funds holding PRAH

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NIPH

NN Investment Partners Holdings The Hague, Netherlands $18.6B AUM 18.31% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Aperio Group's PRAH Position: Q4 2020 in Review

Aperio Group increased its PRA Health Sciences, Inc. (PRAH) stake by 101% in Q4 2020, buying an estimated $2.54M and bringing the position to 45,182 shares worth $5.67M. The position accounts for 0.02% of the portfolio, ranked #771.

Aperio Group first reported a position in PRAH in Q2 2017 and has held it in 15 quarters since. 289 funds tracked by Wall St. Rank hold PRAH as of Q4 2020.

Aperio Group held 45,182 shares of PRA Health Sciences, Inc. worth $5.67M as of Q4 2020.
Aperio Group bought 22,747 PRA Health Sciences, Inc. shares in Q4 2020, an estimated $2.54M.
PRA Health Sciences, Inc. made up 0.02% of Aperio Group's portfolio in Q4 2020, its #771 holding.
Aperio Group first reported a position in PRA Health Sciences, Inc. in Q2 2017 and has held it in 15 quarters since.
289 funds tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.